Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
CRSP
Stock Latest News
The Fly
Crispr Therapeutics durability data ‘encouraging,’ says Morgan Stanley
9d ago
CRSP
Premium
The Fly
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
1M ago
CRSP
Premium
The Fly
Crispr Therapeutics price target lowered to $82 from $83 at BofA
1M ago
CRSP
Premium
The Fly
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
1M ago
CRSP
Premium
Ratings
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
1M ago
CRSP
Premium
Ratings
Analyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
1M ago
CRSP
Premium
Ratings
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
1M ago
CRSP
Premium
Ratings
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
1M ago
CRSP
Premium
The Fly
Citi ups Crispr Therapeutics target on Casgvey momentum
1M ago
CRSP
Premium
The Fly
Crispr Therapeutics price target raised to $88 from $82 at Citi
1M ago
CRSP
Premium
The Fly
Crispr Therapeutics reports Q2 EPS (94c), consensus ($1.18)
1M ago
CRSP
Premium
Company Announcements
Crispr Therapeutics Expands Autoimmune Pipeline With New CTX112 Trial
2M ago
CRSP
Premium
Weekend Updates
Crispr Therapeutics AG Slides Despite Bullish Wall Street
2M ago
CRSP
Premium
Ratings
CRISPR Therapeutics: Buy Rating Reiterated as Pediatric CASGEVY Label Expands; $80 Price Target Maintained
2M ago
CRSP
Premium
Ratings
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts
2M ago
CRSP
Premium
Weekend Updates
Nutrien, CAVA, Cracker Barrel, ADMA, CRISPR Trending With Analysts
3M ago
NTR
ADMA
Premium
The Fly
Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO
3M ago
GS
TP
Premium
The Fly
Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley
3M ago
CRSP
Premium
Company Announcements
Shareholders Approve New Incentive Plan and Governance Measures
3M ago
8K
CRSP
Premium
The Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
3M ago
AZN
BMY
Premium
Company Announcements
Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial
4M ago
CRSP
Premium
The Fly
Crispr Therapeutics price target raised to $56 from $50 at Bernstein
4M ago
CRSP
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
